TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
23.06
-0.47 (-2.00%)
At close: 4:00PM EDT

23.06 0.00 (0.00%)
After hours: 5:35PM EDT

Stock chart is not supported by your current browser
Previous Close23.53
Open23.34
Bid23.00 x 1000
Ask0.00 x 4000
Day's Range22.93 - 23.52
52 Week Range10.85 - 33.24
Volume5,714,844
Avg. Volume11,476,441
Market Cap23.486B
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)-15.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est20.43
Trade prices are not sourced from all markets
  • InvestorPlaceyesterday

    New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock

    Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.

  • Benzinga3 days ago

    Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...

  • Business Wire3 days ago

    Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

    Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business. Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. Operating as an ethical, enduring enterprise is critical to continue bringing value to our business, our stakeholders and society,” said Kåre Schultz, President and CEO of Teva.

  • FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%
    Market Realist4 days ago

    FDA Recalls Valsartan Drugs on Impurity Concerns: Teva Fell 1.8%

    On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.

  • Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018
    Motley Fool4 days ago

    Here's How Teva Pharmaceuticals Pulled Off a 28.3% Gain in the First Half of 2018

    Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.

  • 3 Warren Buffett Stocks Worth Buying Now
    Motley Fool6 days ago

    3 Warren Buffett Stocks Worth Buying Now

    These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.

  • MarketWatch6 days ago

    FDA recalls heart drugs made by Teva, others over carcinogen impurity

    The Food and Drug Administration issued a voluntary recall late Friday of high-blood pressure and heart drugs containing the ingredient valsartan because of impurity issues. Affected companies include Teva Pharmaceuticals Industries Ltd. (teva) Solco Healthcare, and Major Pharmaceuticals, the FDA said. The agency said valsartan used in the affected products contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.

  • 4 Warren Buffett Stocks to Buy in Q2 Earnings
    Zacks7 days ago

    4 Warren Buffett Stocks to Buy in Q2 Earnings

    We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.

  • Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
    Zacks9 days ago

    Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • Business Wire9 days ago

    Teva to Report Second Quarter 2018 Financial Results on August 2, 2018

    Teva Pharmaceutical Industries Ltd. (TEVA) announced today that it will release its second quarter 2018 financial results on Thursday, August 2, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its second quarter 2018 results and overall business environment.

  • Teva Announces Launch of Generic Version of Uceris in US
    Market Realist10 days ago

    Teva Announces Launch of Generic Version of Uceris in US

    On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.

  • Associated Press10 days ago

    Correction: Teva-US-HQ Move story

    TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.

  • Business Wire11 days ago

    Teva Announces Launch of a Generic Version of Uceris® in the United States

    Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. “The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Brendan O’Grady, EVP and head of North America Commercial.

  • TEVA or AKRX: Which Is the Better Value Stock Right Now?
    Zacks11 days ago

    TEVA or AKRX: Which Is the Better Value Stock Right Now?

    TEVA vs. AKRX: Which Stock Is the Better Value Option?

  • Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?
    Market Realist11 days ago

    Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

    As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.

  • Up in the air: Teva's 1M square feet of space in the suburbs
    American City Business Journals11 days ago

    Up in the air: Teva's 1M square feet of space in the suburbs

    Pennsylvania economic development officials weren't enticed to make a competing offer to keep Teva in the Philadelphia region, putting its presence in the suburbs in a precarious position.

  • Teva Presented New Data on Fremanezumab: What You Should Know
    Market Realist11 days ago

    Teva Presented New Data on Fremanezumab: What You Should Know

    During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.

  • ACCESSWIRE11 days ago

    Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

    Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • Teva Pharmaceutical Stock in the Week Ended July 6
    Market Realist13 days ago

    Teva Pharmaceutical Stock in the Week Ended July 6

    On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.

  • Analyst Recommendations for Teva Pharmaceutical in July
    Market Realist13 days ago

    Analyst Recommendations for Teva Pharmaceutical in July

    Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.

  • Teva's decision to move North American HQ leaves other sites in jeopardy
    American City Business Journals13 days ago

    Teva's decision to move North American HQ leaves other sites in jeopardy

    Teva will relocate its North American headquarters to New Jersey, leaving questions about future of its operations in other states, including Kansas.

  • 5 Pharmaceutical and Biotech Stocks to Consider for July
    InvestorPlace14 days ago

    5 Pharmaceutical and Biotech Stocks to Consider for July

    On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.

  • Teva moving North America headquarters from North Wales to North Jersey
    American City Business Journals14 days ago

    Teva moving North America headquarters from North Wales to North Jersey

    The generic drug manufacturer, which has about 2,000 employees in the Philadelphia suburbs, said it will continue to have a 'significant presence' in Pennsylvania.

  • ACCESSWIRE21 days ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.